Piramal Healthcare will invest $11 million in its Morpeth facility, UK, to triple its production capacity for hormonal products, including contraceptive pills and hormone replacement therapies.
The Morpeth facility was acquired by the Piramals from Pfizer in 2006. The plant’s expansion, in response to customer demand, will see production capacity increase by two billion tablets a year, the company said.
The facility will include formulation, package coating and tablet-making equipment, and expansion work will commence later this year.
It is expected to become operational in another 18 months, the company said.
The investment follows Piramal Healthcare’s recent announcement of investing $2.5 million in its FDA-approved Grangemouth site — also in the UK — to upgrade one of its antibody drug conjugate (ADC) manufacturing facilities.